β-defensin 39 Inhibitors
β-Defensin 39 inhibitors represent a specialized category of chemical compounds that specifically target and inhibit the activity of β-defensin 39, a small, cationic antimicrobial peptide belonging to the defensin family. Defensins are a group of host defense peptides known for their broad-spectrum antimicrobial activities against bacteria, viruses, and fungi. β-Defensin 39, like other defensins, is characterized by a specific structure comprising a highly conserved β-sheet and three intramolecular disulfide bridges that maintain its stability and functionality. The inhibition of β-defensin 39 by these inhibitors is primarily achieved through direct binding interactions, which block its ability to interact with microbial membranes or interfere with its mechanism of action. This interaction often involves the disruption of the electrostatic and hydrophobic interactions that β-defensin 39 employs to destabilize and permeabilize microbial membranes, thereby neutralizing its antimicrobial properties.
The structural diversity among β-defensin 39 inhibitors is significant, encompassing a range of molecules from small organic compounds to larger peptides and proteins. Each class of inhibitors may target different aspects of β-defensin 39's structure or function. For example, some inhibitors may bind to the peptide's active site, preventing it from interacting with microbial cell walls, while others might induce conformational changes that render the peptide inactive. These inhibitors are often designed or discovered through high-throughput screening techniques, computational modeling, and structure-activity relationship studies, which help identify molecules with high specificity and affinity for β-defensin 39. Understanding the interaction dynamics and binding affinities between β-defensin 39 and its inhibitors is crucial for elucidating their inhibitory mechanisms, which can provide insights into the fundamental biochemistry of host defense peptides and the evolutionary adaptations of microbial pathogens to resist these host defenses.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK inhibitor disrupting JAK-STAT signaling. Ruxolitinib indirectly inhibits β-defensin 39 by interfering with the activation of STAT proteins, key regulators of β-defensin 39 transcription. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor affecting the MAPK pathway. SB203580 indirectly hampers β-defensin 39 by disrupting the p38 MAPK pathway, known to modulate β-defensin 39 expression through specific transcription factors. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor disrupting PI3K/AKT signaling. Wortmannin indirectly suppresses β-defensin 39, as PI3K/AKT signaling regulates β-defensin 39 transcription through specific transcription factors. | ||||||
A77 1726 | 163451-81-8 | sc-207235 | 10 mg | $80.00 | 14 | |
JAK/STAT pathway inhibitor. A771726 indirectly influences β-defensin 39 by blocking JAK/STAT signaling, crucial for the activation of transcription factors involved in β-defensin 39 expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor disrupting PI3K/AKT signaling. LY294002 indirectly hinders β-defensin 39, as PI3K/AKT signaling is implicated in the regulation of β-defensin 39 transcription by modulating specific transcription factors. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK inhibitor influencing the MAPK/ERK pathway. Trametinib indirectly influences β-defensin 39 expression by disrupting the MAPK/ERK pathway, which modulates β-defensin 39 transcription through specific downstream effectors. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor affecting the AP-1 pathway. SP600125 indirectly hampers β-defensin 39, as the AP-1 transcription factor, downstream of JNK, is involved in the transcriptional regulation of β-defensin 39. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
HDAC inhibitor modulating chromatin structure. Vorinostat indirectly suppresses β-defensin 39 by altering histone acetylation, influencing the accessibility of the β-defensin 39 gene for transcription. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
Wnt/β-catenin pathway inhibitor. XAV939 indirectly inhibits β-defensin 39, as the Wnt/β-catenin pathway is implicated in regulating β-defensin 39 expression by modulating the activity of specific transcription factors. | ||||||
Deferoxamine mesylate | 138-14-7 | sc-203331 sc-203331A sc-203331B sc-203331C sc-203331D | 1 g 5 g 10 g 50 g 100 g | $255.00 $1060.00 $2923.00 $4392.00 $8333.00 | 19 | |
HIF-1α inhibitor affecting the hypoxia pathway. Deferoxamine indirectly suppresses β-defensin 39, as HIF-1α enhances β-defensin 39 transcription under hypoxic conditions, and inhibiting HIF-1α disrupts this regulatory mechanism. | ||||||